| Key Points . |
|---|
| • Exploit already generated and available data to combine with novel proteomics-based searches in order to expand the data set of GBM-relevant TAAs, thereby expanding the repertoire and understanding of the antigenic properties of TAAs in GBM |
| • Characterize the heterogeneity, frequency of TAA recognition, and safety profile of immunogenic TAAs |
| • Re-evaluate immunotherapy clinical trials for the expression, presentation, and recognition of well-characterized TAAs in order to develop more effective combination therapies |
| • Develop more robust selection criteria for patients entering immunotherapy clinical trials to assure patients are “immune-responsive” |
| Key Points . |
|---|
| • Exploit already generated and available data to combine with novel proteomics-based searches in order to expand the data set of GBM-relevant TAAs, thereby expanding the repertoire and understanding of the antigenic properties of TAAs in GBM |
| • Characterize the heterogeneity, frequency of TAA recognition, and safety profile of immunogenic TAAs |
| • Re-evaluate immunotherapy clinical trials for the expression, presentation, and recognition of well-characterized TAAs in order to develop more effective combination therapies |
| • Develop more robust selection criteria for patients entering immunotherapy clinical trials to assure patients are “immune-responsive” |
| Key Points . |
|---|
| • Exploit already generated and available data to combine with novel proteomics-based searches in order to expand the data set of GBM-relevant TAAs, thereby expanding the repertoire and understanding of the antigenic properties of TAAs in GBM |
| • Characterize the heterogeneity, frequency of TAA recognition, and safety profile of immunogenic TAAs |
| • Re-evaluate immunotherapy clinical trials for the expression, presentation, and recognition of well-characterized TAAs in order to develop more effective combination therapies |
| • Develop more robust selection criteria for patients entering immunotherapy clinical trials to assure patients are “immune-responsive” |
| Key Points . |
|---|
| • Exploit already generated and available data to combine with novel proteomics-based searches in order to expand the data set of GBM-relevant TAAs, thereby expanding the repertoire and understanding of the antigenic properties of TAAs in GBM |
| • Characterize the heterogeneity, frequency of TAA recognition, and safety profile of immunogenic TAAs |
| • Re-evaluate immunotherapy clinical trials for the expression, presentation, and recognition of well-characterized TAAs in order to develop more effective combination therapies |
| • Develop more robust selection criteria for patients entering immunotherapy clinical trials to assure patients are “immune-responsive” |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
